EGFR and ovarian carcinoma: Furthermore, Kankia et al. [10] demonstrated NRF2 regulation of HER1 expression and the modulatory effect of NRF2 on the sensitisation of ovarian cancer cells to receptor tyrosine kinases inhibitors (RTKi) and anticancer drugs targeting HER1/HER2 receptors.